Roche has signed a definitive agreement with innovatis, a provider of automated cell analysis solutions, pursuant to which, Roche will acquire 100% of innovatis for E15m. This acquisition is expected to complement Roche’s product portfolio in the area of cellular analytics.
innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the diagnostic division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science’s extensive worldwide network.
The transaction is expected to be completed shortly, subject to shareholder approval and regulatory clearance.
Jurgen Schwiezer, CEO of Roche Diagnostics division, said: This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market. innovatis’s technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008.
Roche is a research-focused healthcare group in pharmaceuticals and diagnostics. The company is an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases. Roche is also in in-vitro diagnostics and drugs for cancer, transplantation, and virology.